Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas (CG118)Product type:GuidanceProgramme:Clinical guidelineLast updated: 20 September 2022Published: 23 March 2011
Crohn’s disease: management (NG129)Product type:GuidanceProgramme:NICE guidelinePublished: 3 May 2019
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 March 2024
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)Product type:GuidanceProgramme:HealthTech guidancePublished: 2 October 2013
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 June 2022
Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 August 2025
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 August 2025
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 February 2015
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2010
Infliximab for acute exacerbations of ulcerative colitis (TA163)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 December 2008
Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 July 2025
Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 October 2023
Ozanimod for treating moderately to severely active ulcerative colitis (TA828)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 October 2022
PredictSURE IBD and IBDX to guide treatment of Crohn’s disease (HTG610)Product type:GuidanceProgramme:HealthTech guidancePublished: 23 February 2022
Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 May 2023
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2024
SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)Product type:GuidanceProgramme:HealthTech guidancePublished: 17 November 2021
Therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)Product type:GuidanceProgramme:HealthTech guidancePublished: 17 February 2016
Tofacitinib for moderately to severely active ulcerative colitis (TA547)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2018
Ulcerative colitis: management (NG130)Product type:GuidanceProgramme:NICE guidelinePublished: 3 May 2019
Upadacitinib for previously treated moderately to severely active Crohn’s disease (TA905)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 January 2023
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment (TA456)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 June 2020
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) (TA826)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 August 2015
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2015